A phase I/II trial of CJC 1134 as a single dose in patients with stable type 2 diabetes mellitus who were receiving metformin therapy.

Trial Profile

A phase I/II trial of CJC 1134 as a single dose in patients with stable type 2 diabetes mellitus who were receiving metformin therapy.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Feb 2007

At a glance

  • Drugs Albenatide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors ConjuChem
  • Most Recent Events

    • 15 Feb 2007 Status change
    • 16 Oct 2006 Status change
    • 14 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top